BioCentury
ARTICLE | Clinical News

Filgotinib meets in Phase II for ankylosing spondylitis

September 21, 2018 4:42 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that once-daily 200 mg oral filgotinib met the primary endpoint of reducing mean Ankylosing Spondylitis Disease Activity Score (ASDAS) from baseline to week 12 vs. placebo in the Phase II TORTUGA trial to treat ankylosing spondylitis (1.5 vs. 0.6 points, p<0.0001). Additionally, a significantly greater proportion of patients who received filgotinib achieved an Assessment of Spondyloarthritis International Society 20 (ASAS20) response at week 12 vs. placebo (76% vs. 40%, p<0.0001).

The double-blind, European trial enrolled 116 patients with moderately to severely active ankylosing spondylitis. The partners plan to submit the data for presentation at a scientific meeting...

BCIQ Target Profiles

Janus kinase-1 (JAK-1)